PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31772161-0	2019	Erlotinib overcomes paclitaxel-resistant cancer stem cells by blocking the EGFR-CREB/GRbeta-IL-6 axis in MUC1-positive cervical cancer.	erlotinib	0-9	mucin 1, cell surface associated	Homo sapiens	105-109	
31772161-9	2019	Collectively, our work has demonstrated that the MUC1-EGFR-CREB/GRbeta axis stimulates IL-6 expression to induce CSCs enrichment and importantly, this effect can be abrogated by erlotinib, uncovering a novel strategy to treat paclitaxel-resistant cervical cancer.	erlotinib	178-187	mucin 1, cell surface associated	Homo sapiens	49-53